SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001564590-22-009645
Filing Date
2022-03-10
Accepted
2022-03-10 16:15:29
Documents
14
Period of Report
2022-03-10
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K onct-8k_20220310.htm   iXBRL 8-K 39312
2 EX-99.1 onct-ex991_6.htm EX-99.1 137730
3 GRAPHIC gi3wn21bjot5000001.jpg GRAPHIC 7888
  Complete submission text file 0001564590-22-009645.txt   330027

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA onct-20220310.xsd EX-101.SCH 5697
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE onct-20220310_lab.xml EX-101.LAB 19424
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE onct-20220310_pre.xml EX-101.PRE 11587
8 EXTRACTED XBRL INSTANCE DOCUMENT onct-8k_20220310_htm.xml XML 3566
Mailing Address 12230 EL CAMINO REAL SUITE 300 SAN DIEGO CA 92130
Business Address 12230 EL CAMINO REAL SUITE 300 SAN DIEGO CA 92130 (858) 434-1113
Oncternal Therapeutics, Inc. (Filer) CIK: 0001260990 (see all company filings)

IRS No.: 621715807 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-50549 | Film No.: 22729216
SIC: 2834 Pharmaceutical Preparations